dc.contributor.author | Martos-Folgado, Inmaculada | |
dc.contributor.author | Del Monte-Monge, Alberto | |
dc.contributor.author | Lorenzo, Cristina | |
dc.contributor.author | Busse, Christian E | |
dc.contributor.author | Delgado, Pilar | |
dc.contributor.author | Mur, Sonia M | |
dc.contributor.author | Cobos-Figueroa, Laura | |
dc.contributor.author | Escolà-Gil, Joan C | |
dc.contributor.author | Martín-Ventura, Jose L | |
dc.contributor.author | Wardemann, Hedda | |
dc.contributor.author | Ramiro, Almudena R | |
dc.date.accessioned | 2022-12-02T11:51:18Z | |
dc.date.available | 2022-12-02T11:51:18Z | |
dc.date.issued | 2022-10-11 | |
dc.identifier.citation | Cell Rep. 2022 Oct 11;41(2):111468 | es_ES |
dc.identifier.uri | http://hdl.handle.net/20.500.12105/15256 | |
dc.description.abstract | Atherosclerosis is a chronic inflammatory disease of the arteries that can lead to thrombosis, infarction, and stroke and is the leading cause of mortality worldwide. Immunization of pro-atherogenic mice with malondialdehyde-modified low-density lipoprotein (MDA-LDL) neo-antigen is athero-protective. However, the immune response to MDA-LDL and the mechanisms responsible for this athero-protection are not completely understood. Here, we find that immunization of mice with MDA-LDL elicits memory B cells, plasma cells, and switched anti-MDA-LDL antibodies as well as clonal expansion and affinity maturation, indicating that MDA-LDL triggers a bona fide germinal center antibody response. Further, Prdm1fl/flAicda-Cre+/kiLdlr-/- pro-atherogenic chimeras, which lack germinal center-derived plasma cells, show accelerated atherosclerosis. Finally, we show that MDA-LDL immunization is not athero-protective in mice lacking germinal-center-derived plasma cells. Our findings give further support to the development of MDA-LDL-based vaccines for the prevention or treatment of atherosclerosis. | es_ES |
dc.description.sponsorship | We thank all members of the B Cell Biology Laboratory for useful discussions, A.
Rodriguez-Ronchel for the design of the graphical abstract, V.G. de Ye´benes for
critical reading of the manuscript, and V. Labrador for help with microscopy and
image analysis. I.M.-F. and C.L. were fellows of the research training program
funded by Ministerio de Economı´a y Competitividad (SVP-2014-068216 and
SVP-2014-068289, respectively), A.d.M.M. is funded by ‘‘la Caixa’’ Foundation
HR17–00247, and A.R.R. was supported by Centro Nacional de Investigaciones
Cardiovasculares (CNIC). The project leading to these results has received funding from la Caixa Banking Foundation under the project code HR17-00247 and
from SAF2016-75511-R and PID2019-106773RB-I00/AEI/10.13039/501100
011033 grants to A.R.R. (Plan Estatal de Investigacio´ n Cientı´fica y Te´ cnica y
de Innovacio´ n 2013–2016 Programa Estatal de I+D+i Orientada a los Retos de
la Sociedad Retos Investigacio´ n: Proyectos I + D + i 2016, Ministerio de Economı´a,Industria y Competitividad) and co-funding by Fondo Europeo de Desarrollo
Regional (FEDER). CIBERCV (J.L.M.-V.) and CIBERDEM (J.C.E.-G.) are Instituto
de Salud Carlos III projects. The CNIC is supported by the Instituto de Salud Carlos III (ISCIII), the Ministerio de Ciencia e Innovacio´ n (MCIN), and the Pro CNIC
Foundation and is a Severo Ochoa institute (CEX2020-001041-S grant funded
by MCIN/AEI/10.13039/501100011033). | es_ES |
dc.language.iso | eng | es_ES |
dc.publisher | Cell Press | es_ES |
dc.type.hasVersion | VoR | es_ES |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ | * |
dc.subject.mesh | Atherosclerosis | es_ES |
dc.subject.mesh | Vaccines | es_ES |
dc.subject.mesh | Animals | es_ES |
dc.subject.mesh | Antibody Formation | es_ES |
dc.subject.mesh | Germinal Center | es_ES |
dc.subject.mesh | Lipoproteins, LDL | es_ES |
dc.subject.mesh | Malondialdehyde | es_ES |
dc.subject.mesh | Mice | es_ES |
dc.subject.mesh | Vaccination | es_ES |
dc.title | MDA-LDL vaccination induces athero-protective germinal-center-derived antibody responses. | es_ES |
dc.type | journal article | es_ES |
dc.rights.license | Atribución 4.0 Internacional | * |
dc.identifier.pubmedID | 36223741 | es_ES |
dc.format.volume | 41 | es_ES |
dc.format.number | 2 | es_ES |
dc.format.page | 111468 | es_ES |
dc.identifier.doi | 10.1016/j.celrep.2022.111468 | es_ES |
dc.contributor.funder | Ministerio de Economía y Competitividad (España) | es_ES |
dc.contributor.funder | Ministerio de Ciencia e Innovación (España) | es_ES |
dc.contributor.funder | Fundación La Caixa | es_ES |
dc.contributor.funder | Fundación ProCNIC | es_ES |
dc.contributor.funder | Ministerio de Economía, Industria y Competitividad (España) | es_ES |
dc.contributor.funder | Unión Europea. Fondo Europeo de Desarrollo Regional (FEDER/ERDF) | es_ES |
dc.contributor.funder | Centro de Investigación Biomédica en Red - CIBERCV (Enfermedades Cardiovasculares) | es_ES |
dc.contributor.funder | Centro de Investigación Biomédica en Red - CIBERDEM (Diabetes y Enfermedades Metabólicas asociadas) | es_ES |
dc.contributor.funder | Instituto de Salud Carlos III | es_ES |
dc.contributor.funder | Ministerio de Ciencia e Innovación. Centro de Excelencia Severo Ochoa (España) | es_ES |
dc.description.peerreviewed | Sí | es_ES |
dc.identifier.e-issn | 2211-1247 | es_ES |
dc.relation.publisherversion | 10.1016/j.celrep.2022.111468 | es_ES |
dc.identifier.journal | Cell reports | es_ES |
dc.repisalud.orgCNIC | CNIC::Grupos de investigación::Biología de linfocitos B | es_ES |
dc.repisalud.institucion | CNIC | es_ES |
dc.rights.accessRights | open access | es_ES |
dc.relation.projectFECYT | info:eu-repo/grantAgreement/ES/SVP-2014-068216 | es_ES |
dc.relation.projectFECYT | info:eu-repo/grantAgreement/ES/HR17–00247 | es_ES |
dc.relation.projectFECYT | info:eu-repo/grantAgreement/ES/CEX2020-001041-S | es_ES |
dc.relation.projectFECYT | info:eu-repo/grantAgreement/ES/MCIN/AEI/10.13039/501100011033 | es_ES |